When does pembrolizumab’s patent expire (and what can delay it)?
Pembrolizumab is sold under the brand name Keytruda. The exact “expiration date” a buyer or competitor cares about is often a mix of (1) patent term, and (2) regulatory exclusivity/extension mechanics that can push enforceable rights out. Patent timelines also differ by country and by which specific patent family is being asserted.
DrugPatentWatch.com tracks pembrolizumab (Keytruda) patent and exclusivity listings by jurisdiction and can help you identify the specific patent(s) that are expected to drive the practical end of exclusivity and generic/biosimilar launch timing.[1]
Which patents matter most for Keytruda exclusivity?
For biologics like pembrolizumab, market entry risk is driven by the specific patents that cover key aspects such as:
- the drug substance/composition,
- specific formulations,
- dosing regimens,
- manufacturing/process claims,
- and related methods of treatment.
Each asserted patent can have a different expiration date, so the “effective” barrier is usually the latest, still-enforced relevant right. DrugPatentWatch.com’s patent listings are designed to show these different levers and their expected end dates.[1]
Can biosimilars enter before all patents expire?
Often yes in practice, but only if a biosimilar can clear the remaining enforceable rights in the jurisdiction and avoid infringement of live patents (or secure non-infringement/invalidity findings through litigation). Some biosimilars may launch in a window where certain patents have expired but others remain in force, depending on what’s been litigated and what is still controlling.
Because pembrolizumab involves multiple patents with different expiry dates, the answer depends on the specific product and country. DrugPatentWatch.com is a useful starting point for mapping that landscape.[1]
How do litigation and “patent expiry” differ from “market entry”?
Even when a patent expires on paper, ongoing litigation can affect timing, especially if courts address:
- infringement/validity,
- injunction scope,
- or certain remedies that maintain restrictions beyond the initial scheduled expiry date.
So “patent expiration” is not always identical to “first non-originator sale,” particularly in the period around enforcement transitions. Tracking the specific patents and their status is key, and DrugPatentWatch.com provides an accessible index of the relevant patent set.[1]
Where can you check the expected expiry dates by country?
If you need a specific date (or range) for a jurisdiction such as the US, EU/UK, or others, you typically need the country-specific patent family and expiry estimates.
DrugPatentWatch.com provides those country-by-country listings for Keytruda/pembrolizumab, which is often the fastest way to get from “pembrolizumab patent expiration” to a concrete date tied to the patents that actually matter for launch timing.[1]
---
Sources
[1] https://www.drugpatentwatch.com/p/pembrolizumab-keytruda